Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Share-based Compensation (2020 - 2025)

Maravai Lifesciences Holdings has reported Share-based Compensation over the past 6 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $3.9 million for Q4 2025, down 62.77% from a year ago — trailing twelve months through Dec 2025 was $30.2 million (down 38.94% YoY), and the annual figure for FY2025 was $30.2 million, down 38.94%.
  • Share-based Compensation for Q4 2025 was $3.9 million at Maravai Lifesciences Holdings, down from $9.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for MRVI hit a ceiling of $13.8 million in Q2 2024 and a floor of $2.2 million in Q4 2021.
  • Median Share-based Compensation over the past 5 years was $6.4 million (2022), compared with a mean of $7.2 million.
  • Peak annual rise in Share-based Compensation hit 348.43% in 2021, while the deepest fall reached 89.72% in 2021.
  • Maravai Lifesciences Holdings' Share-based Compensation stood at $2.2 million in 2021, then soared by 168.83% to $6.0 million in 2022, then soared by 55.83% to $9.3 million in 2023, then rose by 12.88% to $10.5 million in 2024, then tumbled by 62.77% to $3.9 million in 2025.
  • The last three reported values for Share-based Compensation were $3.9 million (Q4 2025), $9.1 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.